Viomycin is a cyclic peptide antibiotic belonging to the viomycin family of streptothricin-like compounds. It is produced by certain actinomycete bacteria, primarily Streptomyces species such as Streptomyces terrae and Streptomyces lividans. Discovered in the 1950s, viomycin has historically been used as a second‑line therapeutic agent in the treatment of multidrug‑resistant tuberculosis (MDR‑TB), often in combination with other antitubercular drugs such as streptomycin and ethambutol.
Chemical structure and properties
- Molecular formula: C₃₆H₆₈N₁₄O₁₀
- Molecular weight: Approximately 785 g·mol⁻¹
- Structure: Viomycin is a non‑ribosomal peptide composed of several unusual amino acid residues, including β‑hydroxylysine, N‑methylated residues, and a terminal amidated group. The molecule forms a cyclic core that is essential for its biological activity.
Mechanism of action
Viomycin exerts its antibacterial effect by binding to the 30S subunit of bacterial ribosomes. Specifically, it interacts with the A‑site of the ribosomal RNA, interfering with the translocation step of protein synthesis. This binding impedes the proper positioning of transfer RNA (tRNA) and leads to premature termination of peptide chain elongation. The drug exhibits a bacteriostatic effect at low concentrations and a bactericidal effect at higher concentrations.
Spectrum of activity
The antibiotic shows potent activity against Mycobacterium tuberculosis and other mycobacterial species. Its efficacy against non‑mycobacterial organisms is limited; it is generally inactive against most Gram‑positive and Gram‑negative bacteria at clinically relevant concentrations.
Clinical use
Viomycin is administered parenterally, typically via intramuscular injection. Due to its nephrotoxic and ototoxic potential, its use is restricted to cases where first‑line anti‑TB drugs are ineffective or contraindicated. Monitoring of renal function and auditory capacity is recommended during therapy.
Resistance
Resistance to viomycin can arise through several mechanisms:
- Mutations in ribosomal RNA genes that reduce drug binding affinity.
- Enzymatic modification of the antibiotic, such as acetylation, mediated by viomycin acetyltransferases encoded by the vio gene cluster.
- Efflux pumps that decrease intracellular drug concentration.
These resistance mechanisms have contributed to the decline in viomycin’s role in modern anti‑TB regimens, as newer, less toxic agents have become available.
Synthesis
In the producing organism, viomycin is assembled by a non‑ribosomal peptide synthetase (NRPS) complex encoded by the vio gene cluster. The biosynthetic pathway involves the activation and condensation of atypical amino acid precursors, followed by cyclization and post‑synthetic tailoring steps, including methylation and hydroxylation. Chemical synthesis of viomycin has been reported but remains complex due to the molecule’s structural intricacy.
Safety and side effects
Common adverse effects include:
- Nephrotoxicity (renal impairment)
- Ototoxicity (hearing loss, vestibular dysfunction)
- Gastrointestinal disturbances (nausea, vomiting)
Because of these risks, therapeutic drug monitoring and dose adjustment are advised, particularly in patients with pre‑existing renal impairment.
Regulatory status
Viomycin is not listed among first‑line antitubercular agents by the World Health Organization (WHO). It may be available in limited formulations in certain countries for specialized use under medical supervision. Its production has largely been superseded by newer agents such as linezolid, bedaquiline, and pretomanid, which offer improved safety profiles and efficacy against resistant mycobacterial strains.
Historical context
The discovery of viomycin contributed to the early expansion of antimicrobial therapy against tuberculosis, illustrating the potential of soil‑derived actinomycetes as sources of clinically valuable antibiotics. Research on viomycin’s structural features also informed the development of other ribosome‑targeting drugs.